Compare CVS Health Corp (CVS) vs Lucid Group Inc (LCID) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Lucid Group Inc — how do they compare? CVS Health Corp trades at $86.2 (market cap $112.49B), while Lucid Group Inc trades at $3.86 (market cap $1.53B). The key difference: CVS Health Corp is far larger — about 73.5× Lucid Group Inc's market cap, and CVS Health Corp pays a 3.02% dividend while Lucid Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Lucid Group Inc for 45 Days on average.
| CVS | LCID | |
|---|---|---|
Market Cap | $112.49B | $1.53B |
Volume | 8,467,392 | 12,739,758 |
Sector | Health | Consumer Cyclical |
52-Week High | $110.60 | $21.92 |
52-Week Low | $70.08 | $3.82 |
Typical Hold Time | 83 Days | 45 Days |
Enterprise Value | $174.83B | $4.43B |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
Lucid Group (LCID) trades at $3.82, down 8.17% with bearish technical signals and negative financial metrics. The company reported significant losses with -249.21% net income margin and missed earnings expectations for three consecutive quarters. Recent developments include strategic partnerships for autonomous vehicles but also product delays and cash burn concerns.
The outlook remains challenging with substantial financial losses and negative cash flow, though analyst consensus suggests potential upside to $7.60. Key risks include execution delays, high cash burn, and competitive pressures in the EV market. The stock faces make-or-break execution challenges in its turnaround efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →
